(2/3)
Catalyst rich 2020. 
1) wholly-owned programs AAV-AQP1 in xerostomia and AAV-GAD inParkinson’s 
2) $JNJ collab partnering program AAV-RPGR for XLRP. cGMP plasmidproduction on track to be operational by YE20